Laura Ruiz-Canas
Overview
Explore the profile of Laura Ruiz-Canas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Palencia-Campos A, Ruiz-Canas L, Abal-Sanisidro M, Lopez-Gil J, Batres-Ramos S, Saraiva S, et al.
J Nanobiotechnology
. 2024 Dec;
22(1):795.
PMID: 39719597
Background: Pancreatic ductal adenocarcinoma (PDAC) requires innovative therapeutic strategies to counteract its progression and metastatic potential. Since the majority of patients are diagnosed with advanced metastatic disease, treatment strategies targeting...
2.
Mirasierra M, Fernandez-Perez A, Lizarbe B, Keiran N, Ruiz-Canas L, Casarejos M, et al.
Cell Mol Life Sci
. 2024 Aug;
81(1):343.
PMID: 39129011
The coordination of food intake, energy storage, and expenditure involves complex interactions between hypothalamic neurons and peripheral tissues including pancreatic islets, adipocytes, muscle, and liver. Previous research shows that deficiency...
3.
Lopez-Gil J, Garcia-Silva S, Ruiz-Canas L, Navarro D, Palencia-Campos A, Giraldez-Trujillo A, et al.
Gut
. 2024 May;
73(9):1489-1508.
PMID: 38754953
Objective: Pancreatic ductal adenocarcinoma (PDAC) has limited therapeutic options, particularly with immune checkpoint inhibitors. Highly chemoresistant 'stem-like' cells, known as cancer stem cells (CSCs), are implicated in PDAC aggressiveness. Thus,...
4.
Melones-Herrero J, Alcala S, Ruiz-Canas L, Benitez-Buelga C, Batres-Ramos S, Cales C, et al.
Commun Biol
. 2024 Mar;
7(1):353.
PMID: 38519773
Cisplatin-based chemotherapy has associated clinical disadvantages, such as high toxicity and resistance. Thus, the development of new antitumor metallodrugs able to overcome different clinical barriers is a public healthcare priority....
5.
Alcala S, Villarino L, Ruiz-Canas L, Couceiro J, Martinez-Calvo M, Palencia-Campos A, et al.
J Exp Clin Cancer Res
. 2024 Jan;
43(1):33.
PMID: 38281027
Background: Previous studies by our group have shown that oxidative phosphorylation (OXPHOS) is the main pathway by which pancreatic cancer stem cells (CSCs) meet their energetic requirements; therefore, OXPHOS represents...
6.
Frutos Diaz-Alejo J, April-Monn S, Cihova M, Buocikova V, Lopez J, Urbanova M, et al.
J Vis Exp
. 2023 Jun;
(195).
PMID: 37306424
Tumor organoids are three-dimensional (3D) ex vivo tumor models that recapitulate the biological key features of the original primary tumor tissues. Patient-derived tumor organoids have been used in translational cancer...
7.
Carrion-Marchante R, Pinto-Diez C, Klett-Mingo J, Palacios E, Barragan-Usero M, Perez-Morgado M, et al.
Pharmaceutics
. 2023 Apr;
15(4).
PMID: 37111758
Lung cancer is the leading cause of cancer-related death worldwide. Its late diagnosis and consequently poor survival make necessary the search for new therapeutic targets. The mitogen-activated protein kinase (MAPK)-interacting...
8.
Frank K, Mulero-Sanchez A, Berninger A, Ruiz-Canas L, Bosma A, Gorgulu K, et al.
Cell Rep Med
. 2022 Nov;
3(11):100815.
PMID: 36384095
Over 90% of pancreatic cancers present mutations in KRAS, one of the most common oncogenic drivers overall. Currently, most KRAS mutant isoforms cannot be targeted directly. Moreover, targeting single RAS...
9.
Alonso-Nocelo M, Ruiz-Canas L, Sancho P, Gorgulu K, Alcala S, Pedrero C, et al.
Gut
. 2022 Apr;
72(2):345-359.
PMID: 35428659
Objective: The lysyl oxidase-like protein 2 (LOXL2) contributes to tumour progression and metastasis in different tumour entities, but its role in pancreatic ductal adenocarcinoma (PDAC) has not been evaluated in...
10.
Alcala S, Mayoral-Varo V, Ruiz-Canas L, Lopez-Gil J, Heeschen C, Martin-Perez J, et al.
Int J Mol Sci
. 2020 Dec;
21(23).
PMID: 33287468
The authors recently reported on the potential of targeting SRC kinase signaling in pancreatic cancer stem cells [...].